

Woojin Lee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1343801/wooin-lee-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

3,717
citations

27
h-index

60
g-index

98
ext. papers

4,181
ext. citations

6.3
avg, IF

5.04
L-index

#	Paper	IF	Citations
94	Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. <i>Journal of Pharmaceutical Investigation</i> , 2021 , 51, 483	6.3	1
93	Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo. <i>Pharmacology & Therapeutics</i> , 2021 , 107938	13.9	1
92	Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 10934-10950	8.3	1
91	Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 517-528	3.9	1
90	Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of Taurocholate. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 365-375	3.9	2
89	A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 510-516	3.9	
88	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 376-387	3.9	2
87	Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. <i>Drug Metabolism and Disposition</i> , 2021 , 49, 298-304	4	0
86	Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer. <i>Oncogene</i> , 2020 , 39, 4567-4580	9.2	11
85	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 1615-1622	3.9	1
84	Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides. <i>Journal of Biological Chemistry</i> , 2020 , 295, 17349-17364	5.4	10
83	Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. <i>AAPS Journal</i> , 2020 , 22, 133	3.7	2
82	Phase 0/microdosing approaches: time for mainstream application in drug development?. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 801-818	64.1	17
81	Runx3 inhibits endothelial progenitor cell differentiation and function via suppression of HIF-1 α activity. <i>International Journal of Oncology</i> , 2019 , 54, 1327-1336	4.4	4
80	Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 396-406	4.5	16
79	H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. <i>Scientific Reports</i> , 2019 , 9, 4089	4.9	9
78	Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 4444-4455	8.3	12

77	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. <i>Journal of Controlled Release</i> , 2019 , 302, 148-159	11.7	20
76	Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 845-857	4.5	14
75	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. <i>Nano Letters</i> , 2019 , 19, 8333-8341	11.5	30
74	Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 897-911	5.5	5
73	Development of Epoxyketone-based Immunoproteasome-selective Inhibitors with Enhanced Brain Distribution In Vivo. <i>FASEB Journal</i> , 2019 , 33, 670-19	0.9	
72	Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 368, 79-87	4.7	4
71	Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 740-748	4	12
70	Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. <i>Journal of Pharmaceutical Sciences</i> , 2018 , 107, 1713-1723	3.9	8
69	A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane. <i>Small</i> , 2018 , 14, e1703670	11	27
68	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 186-196	4.5	26
67	Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. <i>Molecular Pharmaceutics</i> , 2018 ,	5.6	15
66	Next-generation proteasome inhibitors for cancer therapy. <i>Translational Research</i> , 2018 , 198, 1-16	11	58
65	Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. <i>Biomaterials</i> , 2018 , 180, 206-224	15.6	68
64	Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. <i>Small</i> , 2018 , 14, e1803601	11	19
63	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 125, 181-192	5.1	12
62	Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 474-482	4.5	3
61	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. <i>Molecular Cancer Research</i> , 2017 , 15, 1096-1105	6.6	10
60	The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking. <i>Biochemical Pharmacology</i> , 2017 , 131, 98-105	6	11

59	Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters. <i>AAPS Journal</i> , 2017 , 19, 1643-1655	3.7	2
58	Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. <i>PLoS ONE</i> , 2017 , 12, e0173247	3.7	16
57	Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 146, 341-346	3.5	4
56	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2017 , 23, 1299-1311	12.9	20
55	Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 96, 28-36	5.1	2
54	Effect of Enhancers on and Skin Permeation and Deposition of S-Methyl--Methionine. <i>Biomolecules and Therapeutics</i> , 2017 , 25, 434-440	4.2	5
53	Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity. <i>Therapeutic Delivery</i> , 2016 , 7, 665-681	3.8	8
52	Emerging immunotherapy for the treatment of esophageal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 667-77	5.9	21
51	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016 , 58, 41-8	4.4	58
50	High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design. <i>ChemBioChem</i> , 2016 , 17, 2115-2117	3.8	9
49	The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 115, 375-82	3.5	4
48	Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. <i>AAPS Journal</i> , 2015 , 17, 535-45	3.7	69
47	Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2015 , 36, 410-415	1.7	1
46	Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 355, 168-73	4.7	29
45	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. <i>International Journal of Nanomedicine</i> , 2015 , 10, 1201-9.3	7.3	13
44	Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes. <i>ChemBioChem</i> , 2015 , 16, 284-92	3.8	3
43	Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 2036-41	8.3	35
42	Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2015 , 104, 3049-59	3.9	23

41	Nanoformulations of Carfilzomib for Improved Metabolic Stability and Anti-Cancer Efficacy. <i>FASEB Journal</i> , 2015 , 29, 620.1	0.9	1
40	A FRET-based approach for identification of proteasome catalytic subunit composition. <i>Molecular BioSystems</i> , 2014 , 10, 196-200		10
39	A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 419-26	3.5	4
38	Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. <i>PLoS ONE</i> , 2014 , 9, e107424	3.7	1
37	Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF- β impact on gastrointestinal cancers driven by secondary bile acids. <i>Cancer Research</i> , 2014 , 74, 2062-72	10.1	58
36	The immunoproteasome as a therapeutic target for hematological malignancies. <i>Current Cancer Drug Targets</i> , 2014 , 14, 537-48	2.8	15
35	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 2073-81	2.8	12
34	Role of hypoxia inducible factor-1 α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. <i>Biochemical Pharmacology</i> , 2013 , 86, 816-23	6	24
33	A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. <i>Molecular Pharmaceutics</i> , 2013 , 10, 406-16	5.6	58
32	PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer. <i>PLoS ONE</i> , 2013 , 8, e73732	3.7	10
31	Inhibitors of the immunoproteasome: current status and future directions. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4140-51	3.3	67
30	Revisiting the role of the immunoproteasome in the activation of the canonical NF- κ B pathway. <i>Molecular BioSystems</i> , 2012 , 8, 2295-302		18
29	Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. <i>Molecular Pharmaceutics</i> , 2012 , 9, 2197-205	5.6	37
28	Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 699-705	3.5	36
27	Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. <i>ChemBioChem</i> , 2012 , 13, 1899-903	3.8	14
26	The immunoproteasome: an emerging therapeutic target. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 2923-30	3	16
25	Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 3794-802	12.9	43
24	Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. <i>Journal of Carcinogenesis</i> , 2011 , 10, 12	1.9	23

23	Targeted Degradation of Proteins by PROTACs. <i>Current Protocols in Chemical Biology</i> , 2010 , 2, 71-87	1.8	3
22	A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 833-8	3.5	47
21	Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1351-64	5.9	18
20	Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. <i>Cancer Research</i> , 2008 , 68, 10315-23	10.1	103
19	Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. <i>Clinical and Experimental Gastroenterology</i> , 2008 , 1, 1-7	3.1	35
18	Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. <i>Journal of Mass Spectrometry</i> , 2008 , 43, 42-52	2.2	8
17	Intestinal drug transporter expression and the impact of grapefruit juice in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 362-70	6.1	334
16	A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. <i>Molecular Endocrinology</i> , 2007 , 21, 1769-80		57
15	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 647-56	1.9	148
14	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. <i>Gastroenterology</i> , 2006 , 130, 1793-806	13.3	492
13	Hepatic uptake of the novel antifungal agent caspofungin. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 676-82	4	98
12	Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. <i>Journal of Biological Chemistry</i> , 2005 , 280, 9610-7	5.4	266
11	Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. <i>Oncologist</i> , 2005 , 10, 104-11	5.7	98
10	Ethnicity-dependent polymorphism in Na ⁺ -taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. <i>Journal of Biological Chemistry</i> , 2004 , 279, 7213-22	5.4	136
9	Transporters and renal drug elimination. <i>Annual Review of Pharmacology and Toxicology</i> , 2004 , 44, 137-66	7.9	188
8	The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. <i>Nature Medicine</i> , 2003 , 9, 220-4	50.5	389
7	eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. <i>Regulatory Peptides</i> , 2003 , 110, 115-22		8
6	Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. <i>Nitric Oxide - Biology and Chemistry</i> , 2003 , 8, 103-10	5	24

5	Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. <i>British Journal of Pharmacology</i> , 2002 , 135, 299-302	8.6	29
4	Differential interactions of nitric oxide donors with rat oxyhemoglobin. <i>Biochemical Pharmacology</i> , 1999 , 58, 671-4	6	8
3	Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. <i>Biopharmaceutics and Drug Disposition</i> , 1998 , 19, 273-7	1.7	4
2	Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. <i>Biopharmaceutics and Drug Disposition</i> , 1998 , 19, 357-64	1.7	20
1	Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. <i>Biopharmaceutics and Drug Disposition</i> , 1996 , 17, 373-420	1.7	2